• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.对比基于 MALDI-TOF 质谱分析的外周血和骨髓流式细胞术用于多发性骨髓瘤患者微小残留病灶的检测。
Br J Haematol. 2020 Jun;189(5):904-907. doi: 10.1111/bjh.16443. Epub 2020 Feb 5.
2
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.质谱分析法与流式细胞术在检测多发性骨髓瘤微小残留病中的比较
Cancer Med. 2021 Oct;10(20):6933-6936. doi: 10.1002/cam4.4254. Epub 2021 Sep 8.
3
Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories.通过质谱和亲和珠检测 M 蛋白：混合 κ-λ 珠的富集可实现临床实验室的快速应用。
Ann Lab Med. 2024 Nov 1;44(6):518-528. doi: 10.3343/alm.2024.0039. Epub 2024 Aug 20.
4
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.多发性骨髓瘤患者干细胞移植后 MASS-fix 检测血清单克隆蛋白的意义。
Br J Haematol. 2021 Apr;193(2):380-385. doi: 10.1111/bjh.17195. Epub 2020 Nov 20.
5
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.基质辅助激光解吸电离飞行时间质谱可将达雷妥尤单抗与 M 蛋白区分开来。
Clin Chim Acta. 2019 May;492:91-94. doi: 10.1016/j.cca.2019.02.017. Epub 2019 Feb 18.
6
MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.基质辅助激光解吸电离飞行时间质谱法能够区分同一种同种型的免疫固定带，判断其为单克隆蛋白还是双克隆蛋白。
Clin Biochem. 2021 Nov;97:67-73. doi: 10.1016/j.clinbiochem.2021.08.001. Epub 2021 Aug 9.
7
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.采用 MALDI-TOF 质谱法在外周血中对接受达雷妥尤单抗为基础的联合治疗的新诊断多发性骨髓瘤患者进行随访。
Clin Chim Acta. 2021 May;516:136-141. doi: 10.1016/j.cca.2021.01.021. Epub 2021 Feb 2.
8
Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.多发性骨髓瘤低疾病负担的监测：应用外周血质谱检测法。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101142. doi: 10.1016/j.beha.2020.101142. Epub 2020 Jan 11.
9
Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.基于质谱的 Ig 可变区靶向方法用于多发性骨髓瘤微小残留病的评估。
J Mol Diagn. 2020 Jul;22(7):901-911. doi: 10.1016/j.jmoldx.2020.04.002. Epub 2020 Apr 14.
10
Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.多发性骨髓瘤可测量残留疾病的高灵敏度检测的方法学考虑因素。
Cytometry B Clin Cytom. 2020 Mar;98(2):161-173. doi: 10.1002/cyto.b.21862. Epub 2019 Dec 23.

引用本文的文献

1
Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.采用质谱法对外周血进行液体活检可检测多发性骨髓瘤患者的原发性髓外疾病。
Sci Rep. 2024 Aug 13;14(1):18777. doi: 10.1038/s41598-024-69408-1.
2
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.基于质谱的多发性骨髓瘤维持治疗期间外周血 M 蛋白评估。
Blood. 2024 Aug 29;144(9):955-963. doi: 10.1182/blood.2024024041.
3
[Minimal residual disease assessment and progress in multiple myeloma].[多发性骨髓瘤的微小残留病评估与进展]
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):203-208. doi: 10.3760/cma.j.cn121090-20230728-00036.
4
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).采用质谱法（EasyM）靶向跟踪血清 M 蛋白监测多发性骨髓瘤患者的微小残留病灶。
Clin Cancer Res. 2024 Mar 15;30(6):1131-1142. doi: 10.1158/1078-0432.CCR-23-2767.
5
Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.多发性骨髓瘤中的微小残留病：过去、现在与未来
Cancers (Basel). 2023 Jul 20;15(14):3687. doi: 10.3390/cancers15143687.
6
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma.液体活检和基于血液的多发性骨髓瘤微小残留病灶评估。
Oncol Res. 2023 May 24;31(3):271-274. doi: 10.32604/or.2023.028668. eCollection 2023.
7
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.新型诱导治疗时代新诊断多发性骨髓瘤患者自体干细胞移植后深化反应。
Transplant Cell Ther. 2022 Nov;28(11):760.e1-760.e5. doi: 10.1016/j.jtct.2022.07.030. Epub 2022 Aug 5.
8
Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse.利用循环肿瘤DNA评估分子残留病以识别复发高危的多发性骨髓瘤患者。
Front Oncol. 2022 Feb 2;12:786451. doi: 10.3389/fonc.2022.786451. eCollection 2022.
9
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.多发性骨髓瘤患者的微小残留病评估：影响重大的微小疾病
Front Oncol. 2022 Jan 26;11:801851. doi: 10.3389/fonc.2021.801851. eCollection 2021.
10
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.

本文引用的文献

1
Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.免疫富集- MALDI-TOF 质谱法直接检测血清中单克隆游离轻链。
Clin Chem. 2019 Aug;65(8):1015-1022. doi: 10.1373/clinchem.2018.299461. Epub 2019 Jun 6.
2
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.基质辅助激光解吸电离飞行时间质谱可将达雷妥尤单抗与 M 蛋白区分开来。
Clin Chim Acta. 2019 May;492:91-94. doi: 10.1016/j.cca.2019.02.017. Epub 2019 Feb 18.
3
Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.多发性骨髓瘤的反应应根据血清而非尿液游离轻链测量来进行评估。
Leukemia. 2019 Feb;33(2):313-318. doi: 10.1038/s41375-018-0339-y. Epub 2018 Dec 20.
4
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.采用深度测序技术从循环肿瘤 DNA 检测多发性骨髓瘤微小残留病灶与骨髓检测结果不相关。
Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197.
5
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.深度测序检测微小残留病灶阴性是多发性骨髓瘤的一个主要预后因素。
Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.
6
Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.质谱法检测多发性骨髓瘤微小残留病中单克隆免疫球蛋白。
Semin Hematol. 2018 Jan;55(1):41-43. doi: 10.1053/j.seminhematol.2018.02.008. Epub 2018 Feb 26.
7
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.多发性骨髓瘤中的微小残留病检测：MSKCC 10色单管法与EuroFlow 8色双管法的比较
Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.
8
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma.多发性骨髓瘤 sCR 患者中高敏血液 M 蛋白检测。
Blood Cancer J. 2017 Aug 25;7(8):e590. doi: 10.1038/bcj.2017.75.
9
How I treat myeloma with new agents.我如何用新药治疗骨髓瘤。
Blood. 2017 Sep 28;130(13):1507-1513. doi: 10.1182/blood-2017-05-743203. Epub 2017 Jul 26.
10
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.内源性免疫球蛋白G代谢的房室模型分析及其在多发性骨髓瘤中的应用
Front Physiol. 2017 Mar 17;8:149. doi: 10.3389/fphys.2017.00149. eCollection 2017.

对比基于 MALDI-TOF 质谱分析的外周血和骨髓流式细胞术用于多发性骨髓瘤患者微小残留病灶的检测。

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

机构信息

Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Hematology Biology, Nantes University Hospital, Nantes, France.

出版信息

Br J Haematol. 2020 Jun;189(5):904-907. doi: 10.1111/bjh.16443. Epub 2020 Feb 5.

DOI:10.1111/bjh.16443
PMID:32026474
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7275888/
Abstract

Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI-TOF-MS head-to-head with an established bone marrow-based measurable residual disease assay by flow cytometry (Flow-BM-MRD), using Memorial Sloan Kettering Cancer Center's 10-color, single-tube method. Our results suggest that MALDI-TOF-MS adds value to bone marrow-based MRD testing and may be most useful for early detection of relapse in peripheral blood compared to current electrophoretic methods.

摘要

基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）可能很快将取代多发性骨髓瘤患者监测单克隆蛋白的常规电泳方法。为了进一步评估该检测方法的临床实用性，我们使用 Memorial Sloan Kettering Cancer Center 的 10 色单管方法，将 MALDI-TOF-MS 与基于骨髓的已建立的可测量残留疾病流式细胞术检测（Flow-BM-MRD）进行了直接比较。我们的结果表明，MALDI-TOF-MS 为基于骨髓的 MRD 检测增添了价值，与目前的电泳方法相比，它可能更有助于早期检测外周血中的复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6496/7275888/540b4280cf17/nihms-1063140-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6496/7275888/540b4280cf17/nihms-1063140-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6496/7275888/540b4280cf17/nihms-1063140-f0001.jpg